Superlatively well-funded biotech startup Juno Therapeutics has bagged another $134 million in venture cash, bringing its 12-month total north of $300 million as it races to advance a new therapeutic approach that could transform cancer treatment.
Roseville, MN-based Rebiotix says it raised $25 million in a Series B, designed to fund pivotal work on its lead fecal-transplant program for RBX2660.
Bristol-Myers Squibb has formed a new joint venture with Boston-based Allied Minds that will hunt the groves of academia in an enterprising approach to launching new biotechs and bagging new drug candidates.
Well-heeled venture capital firm Venrock has pieced together a 7th fund, banking $450 million in new investments as it sets out to grow its portfolio of promising startups.
California biotech Cold Genesys has wrapped up a $13.6 million A round to support its work on cancer treatment that promises to infect tumor cells and convince the immune system to join the fight.
Analysts at Silicon Valley Bank have been crunching the numbers on biotech investing, and they have found that a group of busy corporate venture arms has fundamentally changed the landscape for startups and the entire field of early-state drug development--with some big implications for the current crop of industry upstarts.
Months after a swift exit from Pfizer's highest ranks, Amy Schulman has made her next move, joining high-profile biotech investor Polaris as a venture partner
Three Big Pharma companies have helped come up with some seed money to start growing the first crop of biotechs in New York. Pfizer, Eli Lilly and J&J all chipped in to a $51 million fund from Accelerator Corp., which will now expand on the work it's been doing in Seattle to the East Side of Manhattan, recruiting upstarts to join investigators at the Alexandria Center for Life Science.
Redwood City, CA-based PaxVax has nailed down up to $50 million in debt financing and $12 million in a Series B venture funding extension to complete the acquisition of Crucell's oral typhoid vaccine Vivotif and the ongoing Phase III study of its cholera vaccine candidate, PXVX0200.
Israeli drug developer Atox Bio has raised a $23 million E round to support its treatment for rare, tissue-destroying bacteria, paving the way for late-stage work.